Discontinuation of medication due to adverse events · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Adverse events: death · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).
1 finding from 1 review
Complete remission (no further aphthous episodes to 6 months) · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in treatment response at 6 months: complete remission compared with cyclosporin (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in treatment response at 6 months: complete and partial remission compared with cyclosporin (low certainty).
2 findings from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in treatment response at 12 months: complete remission compared with cyclosporin (low certainty).
1 finding from 1 review
Adverse events: persistent nephrotoxicity · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in adverse events: persistent nephrotoxicity compared with cyclosporin (low certainty).
1 finding from 1 review
Complete remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in complete remission: FSGS compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Sustainable remission between 52 and 78 weeks: complete or partial remission (primary outcome 1, 2, 3) · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Complete response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Complete or partial remission: all renal pathologies · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin may leads to higher complete or partial remission: all renal pathologies compared with placebo or no treatment (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review